Table 2 Antimicrobial susceptibility of Thai Streptococcus suis isolated from human patients (27 strains), diseased pigs (46 strains), and asymptomatic pigs (189 strains)
Antibiotic drugs | Human patients 27 strains | Diseased pigs 46 strains | Asymptomatic pigs 189 strains | P-value | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
S | I | R | S | I | R | S | I | R | Â | |
AMP | 27 (100%) | 0 (0%) | 0 (0%) | 40 (86.9%) | 2 (4.4%) | 4 (8.7%) | 125 (66.1%) | 23 (12.2%) | 41 (21.7%) | 0.001* |
CFL | 27 (100%) | 0 (0%) | 0 (0%) | 34 (73.9%) | 1 (2.2%) | 11 (23.9%) | 104 (55.0%) | 4 (2.1%) | 81 (42.9%) | <  0.001* |
CTX | 27 (100%) | 0 (0%) | 0 (0%) | 38 (82.6%) | 2 (4.4%) | 6 (13.0%) | 179 (94.7%) | 2 (1.1%) | 8 (4.2%) | 0.029* |
CTF | 27 (100%) | 0 (0%) | 0 (0%) | 39 (84.8%) | 3 (6.5%) | 4 (8.7%) | 182 (96.3%) | 2 (1.1%) | 5 (2.6%) | 0.018* |
PEN | 27 (100%) | 0 (0%) | 0 (0%) | 33 (71.7%) | 8 (17.4%) | 5 (10.9%) | 59 (31.2%) | 79 (41.8%) | 51 (27.0%) | <  0.001* |
VAN | 27 (100%) | 0 (0%) | 0 (0%) | 42 (91.3%) | 1 (2.2%) | 3 (6.5%) | 184 (97.4%) | 4 (2.1%) | 1 (0.5%) | 0.042* |
AZM | 5 (18.5%) | 0 (0%) | 22 (81.5%) | 9 (19.6%) | 0 (0%) | 37 (80.4%) | 26 (13.8%) | 4 (2.1%) | 159 (84.1%) | 0.619 |
CHL | 24 (88.9%) | 3 (11.1%) | 0 (0%) | 37 (80.4%) | 4 (8.7%) | 5 (10.9%) | 168 (88.9%) | 10 (5.3%) | 11 (5.8%) | 0.254 |
CLI | 5 (18.5%) | 0 (0%) | 22 (81.5%) | 5 (10.9%) | 0 (0%) | 41 (89.1%) | 7 (3.7%) | 0 (0%) | 182 (96.3%) | 0.006* |
DOX | 0 (0%) | 0 (0%) | 27 (100%) | 2 (4.4%) | 2 (4.4%) | 42 (91.3%) | 22 (11.6%) | 3 (1.6%) | 164 (86.8%) | 0.114 |
ERY | 4 (14.8%) | 4 (14.8%) | 19 (70.4%) | 9 (19.6%) | 1 (2.2%) | 36 (78.2%) | 30 (15.9%) | 2 (1.1%) | 157 (83.0%) | 0.001* |
FFC | 26 (96.3%) | 1 (3.7%) | 0 (0%) | 36 (78.2%) | 0 (0%) | 10 (21.8%) | 180 (95.3%) | 1 (0.5%) | 8 (4.2%) | <  0.001* |
GEN | 22 (81.5%) | 3 (11.1%) | 2 (7.4%) | 11 (23.9%) | 9 (19.6%) | 26 (56.5%) | 67 (35.5%) | 49 (25.9%) | 73 (38.6%) | <  0.001* |
TET | 0 (0%) | 0 (0%) | 27 (100%) | 3 (6.5%) | 2 (4.4%) | 41 (89.1%) | 10 (5.3%) | 5 (2.6%) | 174 (92.1%) | 0.552 |
TIA | 0 (0%) | 23 (85.2%) | 4 (14.8%) | 4 (8.7%) | 5 (10.9%) | 37 (80.4%) | 2 (1.1%) | 17 (9.0%) | 170 (89.9%) | <  0.001* |
CIP | 20 (74.1%) | 5 (18.5%) | 2 (7.4%) | 32 (69.5%) | 5 (10.9%) | 9 (19.6%) | 103 (54.5%) | 26 (13.8%) | 60 (31.7%) | 0.048* |
ENR | 15 (55.6%) | 12 (44.4%) | 0 (0%) | 23 (50.0%) | 15 (32.6%) | 8 (17.4%) | 105 (55.6%) | 29 (15.3%) | 55 (29.1%) | <  0.001* |
NOR | 5 (18.5%) | 19 (70.4%) | 3 (11.1%) | 13 (28.3%) | 13 (28.3%) | 20 (43.4%) | 47 (24.9%) | 41 (21.7%) | 101 (53.4%) | <  0.001* |
LEV | 27 (100%) | 0 (0%) | 0 (0%) | 41 (89.1%) | 1 (2.2%) | 4 (8.7%) | 134 (70.9%) | 5 (2.6%) | 50 (26.5%) | 0.003* |
SXT | 27 (100%) | 0 (0%) | 0 (0%) | 18 (39.1%) | 6 (13.0%) | 22 (47.9%) | 50 (26.5%) | 4 (2.1%) | 135 (71.4%) | <  0.001* |